Telefon:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antikoerper-online.de

TLR9 Antikörper (Toll-Like Receptor 9) Primary Antibody

TLR9 Reaktivität: Human FACS, IF, IHC (p), WB Wirt: Maus Monoclonal 5G5 unconjugated
Pubmed (7 Referenzen)
Produktnummer ABIN2191962
$547.49
Zzgl. Versandkosten $45.00
100 μg
Lieferung in 6 bis 8 Werktagen
  • Target Alle TLR9 Antikörper anzeigen
    TLR9
    Reaktivität
    • 116
    • 51
    • 18
    • 8
    • 7
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    Human
    Wirt
    • 76
    • 40
    • 10
    • 8
    • 1
    • 1
    Maus
    Klonalität
    • 87
    • 49
    Monoklonal
    Konjugat
    • 78
    • 16
    • 15
    • 8
    • 5
    • 4
    • 4
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser TLR9 Antikörper ist unkonjugiert
    Applikation
    • 98
    • 61
    • 57
    • 57
    • 25
    • 16
    • 16
    • 12
    • 9
    • 5
    • 4
    • 3
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB)
    Kreuzreaktivität (Details)
    Cross reactivity: Canine TLR9 : Yes, Mouse TLR9 : Yes
    Sterilität
    0.2 μm filtered
    Klon
    5G5
    Isotyp
    IgG2a
  • Applikationshinweise
    For immunohistochemistry, flow cytometry and Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. Positive RAW264.7 macrophages stimulated with IFNγ control
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Buffer
    PBS, containing 0.1 % bovine serum albumin and 0.02 % sodium azide.
    Vorsichtsmaßnahmen
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    4 °C
    Informationen zur Lagerung
    Product should be stored at 4 °C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.
  • Machida, Ito, Hirose, Takeshita, Oshiro, Nakamura, Mori, Inayama, Yan, Kobayashi, Yokota: "Expression of Toll-like receptor 9 in renal podocytes in childhood-onset active and inactive lupus nephritis." in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 25, Issue 8, pp. 2530-537, (2010) (PubMed).

    Zheng, Wang, Liu, Liu, Feng, Wu, Cao: "Distinct host-related dendritic cell responses during the early stage of Plasmodium yoelii infection in susceptible and resistant mice." in: Parasite immunology, Vol. 32, Issue 5, pp. 324-34, (2010) (PubMed).

    Burgener, Jungi: "Antibodies specific for human or murine Toll-like receptors detect canine leukocytes by flow cytometry." in: Veterinary immunology and immunopathology, Vol. 124, Issue 1-2, pp. 184-91, (2008) (PubMed).

    Tokumasa, Suto, Kagami, Furuta, Hirose, Watanabe, Saito, Shimoda, Iwamoto, Nakajima: "Expression of Tyk2 in dendritic cells is required for IL-12, IL-23, and IFN-gamma production and the induction of Th1 cell differentiation." in: Blood, Vol. 110, Issue 2, pp. 553-60, (2007) (PubMed).

    Pratesi, Petrangolini, Tortoreto, Addis, Belluco, Rossini, Selleri, Rumio, Menard, Balsari: "Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft." in: Cancer research, Vol. 65, Issue 14, pp. 6388-93, (2005) (PubMed).

    Rumio, Besusso, Palazzo, Selleri, Sfondrini, Dubini, Ménard, Balsari: "Degranulation of paneth cells via toll-like receptor 9." in: The American journal of pathology, Vol. 165, Issue 2, pp. 373-81, (2004) (PubMed).

    Rutz, Metzger, Gellert, Luppa, Lipford, Wagner, Bauer: "Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner." in: European journal of immunology, Vol. 34, Issue 9, pp. 2541-50, (2004) (PubMed).

  • Target
    TLR9
    Andere Bezeichnung
    Toll-Like Receptor 9 (TLR9 Produkte)
    Synonyme
    CD289, toll like receptor 9, toll-like receptor 9, TLR9, Tlr9
    Hintergrund
    The monoclonal antibody 5G5 recognizes human Toll-like receptor 9. Toll-like receptors (TLRs) are highly conserved from Drosophila to humans and share structural and functional similarities. TLRs constitute of a family of pattern recognition receptors (PRRs) that mediate cellular responses to a large variety of pathogens (viruses, bacteria, and parasites) by specific recognition of so-called 'pathogen-associated molecular patterns'. Activation of TLRs, a family of at least 11 different members that function either as homo- or heterodimers, leads to activation of NFκB-dependent and IFN- regulatory factor-dependent signaling pathways. TLRs have a central role in innate immunity and are also required for the development of an adaptive immune response. TLRs are expressed by various cells of the immune system, such as macrophages and dendritic cells. They recognize and respond to molecules derived from bacterial, viral and fungal pathogens. Whereas most TLRs are expressed on the cell surface, TLR9 is expressed intracellularly within one or more endosomal compartments and recognizes nucleic acids. TLR9 detects a rather subtle difference in the DNA of vertebrates compared with that of pathogens. Vertebrate genomic DNAs have mostly methylated CpG dinucleotides where bacterial and viral DNAs have unmethylated CpG dinucleotides. TLR9 undergoes relocation from endoplasmic reticulum to CpG-ODN-containing endosomes. In these endosomes TLR9 becomes a functional receptor after proteolytic cleavage. TLR9 exists as a preformed homodimer and CpG-ODN binding promotes its conformational change, bringing the cytoplasmic TIR-like domains close to each other. This allows a recruitment of the key adapter protein MyD88 which initiates a signalling cascade. The only human immune cell types known to constitutively express TLR9 and to be activated by CpG ODN are pDCs and B cells. TLR9 triggering induces an activation phenotype in the B cells and pDCs, characterized by the expression of costimulatory molecules, resistance to apoptosis, and induces Th1-type immune response profiles. Aliases CD289, TLR9 Immunogen Purified fusion protein of extracellular domain of human TLR9 (AA 1-815) and human IgGFc
    Pathways
    TLR Signalweg, Activation of Innate immune Response, Cellular Response to Molecule of Bacterial Origin, Toll-Like Receptors Cascades
Sie sind hier:
Kundenservice